Client: LFB USA
Location: Marlborough, MA
LFB USA is a division of a European biopharmaceutical group that develops, manufactures, and markets medicinal products for the treatment of serious and often rare diseases. With a focus on several major therapeutic fields, including hemostasis, immunology and the intensive care environment, the LFB Group is a leading manufacturer of plasma-derived medicinal products worldwide.
New 72,0000 sq. ft. cGMP Manufacturing Facility
This project began as a new biomanufacturing facility for a drug in development by LFB USA. Having worked with LFB USA for more than 10 years on several projects at their facilities in Framingham and Charlton, company leadership was confident in RP Masiello’s ability to deliver the quality required to meet FDA standards for current Good Manufacturing Practices (cGMP) for biopharmaceuticals.
Halfway through construction LFB halted the project with the intent to re-start it two years later. LFB later changed direction, opting to sell the incomplete building.
Faced with this challenging situation, RP Masiello helped craft a solution that benefited two of its long-standing clients. RP Masiello’s client, First Colony Development bought the partially completed building from LFB USA, modified the design to be more flexible and prepared it for sale to another firm.
RP Masiello has also worked on assorted lab and corporate renovations at their Framingham headquarters, and at their 32-building campus in Charlton. In 2015 RP Masiello constructed a unique 15,000 ft. facility to house their hybrid rabbits. The building entailed complex systems for feeding and waste removal, along with critical plumbing and HVAC requirements for the rabbits. The rabbits were developed for a milk byproduct used in their pharmaceutical process. RP Masiello worked on other structures at the Charlton campus which houses its hybrid goats, used for another byproduct for the company’s drug making process.